Evidence map›Paper›PMID 39917079›Full record

ReviewFrontiers in physiology2025

Promotion of nitric oxide production: mechanisms, strategies, and possibilities.

Marcos Gonzalez, Sarah Clayton, Eric Wauson, Daniel Christian, Quang-Kim Tran

Abstract readReview
In one paragraph

Review in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marcos GonzalezDepartment of Physiology and Pharmacology, Des Moines University Medicine and Health Sciences, West Des Moines, IA, United States.
Sarah ClaytonDepartment of Physiology and Pharmacology, Des Moines University Medicine and Health Sciences, West Des Moines, IA, United States.
Eric WausonDepartment of Physiology and Pharmacology, Des Moines University Medicine and Health Sciences, West Des Moines, IA, United States.
Daniel ChristianDepartment of Physiology and Pharmacology, Des Moines University Medicine and Health Sciences, West Des Moines, IA, United States.
Quang-Kim TranDepartment of Physiology and Pharmacology, Des Moines University Medicine and Health Sciences, West Des Moines, IA, United States.

Funding

Development of a Novel Vasorelaxing PeptideR15HL173818 · NHLBI · DES MOINES UNIV OSTEOPATHIC MEDICAL CTR · PI TRAN, KIM · 2024 to 2024
$453k
GluD1 regulation of structural plasticity in chronic ethanol exposure and protracted withdrawalR03AA031063 · NIAAA · DES MOINES UNIV OSTEOPATHIC MEDICAL CTR · PI CHRISTIAN, DANIEL TOMMIS · 2023 to 2023
$152k
NHLBI NIH HHS R15 HL173818NIAAA NIH HHS R03 AA031063
6 · The paper itself

Abstract

The discovery of nitric oxide (NO) and the role of endothelial cells (ECs) in its production has revolutionized medicine. NO can be produced by isoforms of NO synthases (NOS), including the neuronal (nNOS), inducible (iNOS), and endothelial isoforms (eNOS), and via the non-classical nitrate-nitrite-NO pathway. In particular, endothelium-derived NO, produced by eNOS, is essential for cardiovascular health. Endothelium-derived NO activates soluble guanylate cyclase (sGC) in vascular smooth muscle cells (VSMCs), elevating cyclic GMP (cGMP), causing vasodilation. Over the past four decades, the importance of this pathway in cardiovascular health has fueled the search for strategies to enhance NO bioavailability and/or preserve the outcomes of NO's actions. Currently approved approaches operate in three directions: 1) providing exogenous NO, 2) promoting sGC activity, and 3) preventing degradation of cGMP by inhibiting phosphodiesterase 5 activity. Despite clear benefits, these approaches face challenges such as the development of nitrate tolerance and endothelial dysfunction. This highlights the need for sustainable options that promote endogenous NO production. This review will focus on strategies to promote endogenous NO production. A detailed review of the mechanisms regulating eNOS activity will be first provided, followed by a review of strategies to promote endogenous NO production based on the levels of available preclinical and clinical evidence, and perspectives on future possibilities.

Indexed as

clinical trialsendotheliumeNOSnitric oxidepreclinical evidence

Identifiers

PMID39917079
PMCPMC11799299

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.